secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001297184-25-000058
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party
--------------------------------------------------------------------------------

- Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.
- Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.
- 10-year term; minimum purchase amounts per contract year; profit sharing above floor price.
- Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.
- Audit Committee approved the deal; total revenue over 10 years not yet determinable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/0001297184-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/amph-20251021x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer